Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Introduction: The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD). Methods: A double‐blind, randomized, placebo‐controlled parallel group design using donepezil (10 mg/day) in subjects with suspected prodromal AD. Subjects underwent two brain magnetic resonance imaging scans (baseline and final visit). The primary efficacy outcome was the annualized percentage change (APC) of total hippocampal volume (left + right) measured by an automated segmentation method. Results: Two‐hundred and sixteen only subjects were randomized across 28 French expert clinical sites. In the per protocol population (placebo = 92 and donepezil = 82), the donepezil group exhibited a significant reduced rate of hippocampal atrophy (APC = −1.89%) compared with the placebo group (APC = −3.47%), P < .001. There was no significant difference in neuropsychological performance between treatment groups. Discussion: A 45% reduction of rate of hippocampal atrophy was observed in prodromal AD following 1 year of treatment with donepezil compared with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“…of prodromal Alzheimer’s disease (AD) was recently introduced by the International Working Group on the New Criteria for the diagnosis of AD [1] to describe the stage of AD where clinical symptoms, including episodic memory disorders of the hippocampal type, are present but not sufficiently…”
BackgroundSelf-citationDonepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827 · cited 3×
“Greater hippocampal atrophy has also been observed in patients with rapidly progressing AD relative to those exhibiting slower progression [6].”
BackgroundMethodInfluentialTrajectories of brain loss in aging and the development of cognitive impairment
Carlson, N. E., Moore, M. M., Dame, A., Howieson, D., Silbert, L. C., Quinn, J. F., & Kaye, J. A. (2008) · Neurology · doi:10.1212/01.wnl.0000280577.43413.d9 · Cited by 144 · cited 2×
“An observed decrease of 3.3% of the hippocampal volume in MCI subjects treated with placebo (Jack et al. [2004]) [7].”
BackgroundMethodInfluential
Cited by
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Self-citationIslam, J., & Zhang, Y. (2018) · Brain Informatics · doi:10.1186/s40708-018-0080-3 · Cited by 478
Landmark-based deep multi-instance learning for brain disease diagnosis
Liu, M., Zhang, J., Adeli, E., & Shen, D. (2018) · Medical Image Analysis · doi:10.1016/j.media.2017.10.005 · Cited by 425
Hampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.43 · Cited by 369
Self-citationWalczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Metadata
- Authors
- Dubois, B., Chupin, M., Hampel, H., Lista, S., Cavedo, E., Croisile, B., Louis Tisserand, G., Touchon, J., Bonafe, A., Ousset, P. J., Ait Ameur, A., Rouaud, O., Ricolfi, F., Vighetto, A., Pasquier, F., Delmaire, C., Ceccaldi, M., Girard, N., Dufouil, C., Lehericy, S., Tonelli, I., Duveau, F., Colliot, O., Garnero, L., Sarazin, M., Dormont, D., & “Hippocampus Study Group”
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2015-01-14
- Volume
- 11
- Issue
- 9
- Pages
- 1041-1049
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2065872609
- Cited by
- 140
- References
- 4
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2014.10.003
- The paper
- Dubois, B., Chupin, M., Hampel, H., Lista, S., Cavedo, E., Croisile, B., Louis Tisserand, G., Touchon, J., Bonafe, A., Ousset, P. J., Ait Ameur, A., Rouaud, O., Ricolfi, F., Vighetto, A., Pasquier, F., Delmaire, C., Ceccaldi, M., Girard, N., Dufouil, C., . . . “Hippocampus Study Group”. (2015). Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2014.10.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.